Nectar Lifesciences AGM: Auditors issue clean opinion for FY26

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Nectar Lifesciences held its 31st AGM on September 18, 2026
  • Statutory auditors issued an unqualified opinion for FY26
  • Chairman Sanjiv Goyal was reappointed by rotation
  • Two independent directors were reappointed for their second terms
  • Dr. Gunmala Suri was appointed as a non-executive director
powered bylight_fuzz_icon
51260591

*this image is generated using AI for illustrative purposes only.

Nectar Lifesciences held its 31st annual general meeting on September 18, 2026, where shareholders approved the adoption of standalone and consolidated financial statements for FY26.

The meeting, conducted via video conferencing, saw the reappointment of Chairman Sanjiv Goyal and independent directors Dr. Kuldip Kumar Bhasin and Dr. Indu Pal Kaur. Dr. Gunmala Suri was appointed as a non-executive non-independent director.

Audit and Governance

Statutory auditors M/s. Deepak Jindal & Co., Chartered Accountants, and secretarial auditors P. Chadha & Associates expressed an unqualified opinion on the financial year 2025-26 results. No qualifications or adverse comments were noted in the audit reports regarding the company’s functioning or financial statements.

KFin Technologies Limited served as the registrar and share transfer agent, facilitating remote e-voting from September 15 to September 17, 2026, and instant polling during the AGM. Mr. Prince Chadha acted as the scrutinizer for the voting process.

Board Appointments

The following resolutions were passed during the ordinary and special business segments:

Director Role Action
Sanjiv Goyal Chairman & Managing Director Reappointed by rotation
Dr. Kuldip Kumar Bhasin Independent Director Reappointed for second term
Dr. Indu Pal Kaur Independent Director Reappointed for second term
Dr. Gunmala Suri Non-Executive Non-Independent Director Appointed

Chairman Sanjiv Goyal thanked members for their trust and acknowledged the commitment of the company’s workforce. The meeting concluded at 11:25 am.

Historical Stock Returns for Nectar Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
-0.45%-8.05%-2.32%+0.18%-34.11%-62.75%

How might the appointment of Dr. Gunmala Suri as a non-executive non-independent director influence Nectar Lifesciences' strategic direction and board dynamics?

Given the clean audit opinion for FY26, what specific growth initiatives or capital allocation strategies is management expected to prioritize in the upcoming fiscal year?

Will the reappointment of key independent directors signal continuity in corporate governance standards, or are there anticipated changes to the company's risk management framework?

Nectar Lifesciences schedules 31st AGM for September 18, 2026

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • 31st AGM scheduled for September 18, 2026
  • Meeting conducted via video conference
  • Remote e-voting runs from September 15 to 17
  • Annual Report for FY26 available online
powered bylight_fuzz_icon
48935345

*this image is generated using AI for illustrative purposes only.

Nectar Lifesciences has scheduled its 31st Annual General Meeting for September 18, 2026. The event will be conducted through video conference or other audio-visual means.

The company issued an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure informs shareholders who have not registered email addresses about the availability of the Annual Report for FY26.

Meeting and Voting Schedule

The AGM is set for Friday, September 18, 2026, at 11:00 am IST. Shareholders can participate in remote e-voting during a specific window preceding the meeting. The cut-off date for both the AGM and e-voting is Friday, September 11, 2026.

Event Date and Time
Cut-off date September 11, 2026
E-voting start September 15, 2026, 9:00 am
E-voting end September 17, 2026, 5:00 pm
AGM date September 18, 2026, 11:00 am

Document Access

Electronic copies of the AGM Notice and the Annual Report for FY26 have been sent to shareholders with registered email addresses. For those without registered emails, the documents are accessible via weblinks provided in the intimation letter.

The reports are also available on the company’s website and the listing exchanges’ platforms. Shareholders holding physical shares may contact the Registrar and Share Transfer Agent, KFin Technologies Limited, to register their email addresses for future communications.

Historical Stock Returns for Nectar Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
-0.45%-8.05%-2.32%+0.18%-34.11%-62.75%

What specific financial performance metrics or strategic initiatives for FY26 are likely to be highlighted in the Annual Report to justify shareholder value?

How might the outcome of the e-voting process influence management's decisions on dividend policies or capital allocation for the upcoming fiscal year?

Are there any pending regulatory compliance issues or SEBI observations from previous years that Nectar Lifesciences is expected to address during this AGM?

More News on Nectar Lifesciences

1 Year Returns:-34.11%